<DOC>
	<DOCNO>NCT02834364</DOCNO>
	<brief_summary>Trial patient refractory multiple myeloma failure least two treatment regimen BRAFV600E/K Mutation evaluate efficacy kinase inhibitor Encorafenib ( LGX818 ) combination Binimetinib ( MEK162 ) .</brief_summary>
	<brief_title>BRAF/MEK Inhibition Relapsed/Refractory Multiple Myeloma ( BIRMA )</brief_title>
	<detailed_description>An open-label , single-arm , multi-centre phase II trial patient refractory multiple myeloma BRAFV600E/K Mutation evaluate efficacy kinase inhibitor Encorafenib ( LGX818 ) combination Binimetinib ( MEK162 ) . The patient must receive least two prior therapy regimen ( least one immunomodulatory drug one proteasome inhibitor ) . The subject receive LGX 818 450 mg. p.o . daily MEK 162 45 mg p.o . twice daily disease progression toxicity require discontinuation treatment . 1 cycle define 28 day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Patient provide sign study Informed Consent Form prior studyspecific procedure able comply protocol requirement 2 . Patients multiple myeloma , relapse refractory failure two line systemic treatment . All patient must receive least one immunomodulatory drug ( IMiD ) proteasome inhibitor . Multiple myeloma require systemic therapy must confirm medical history patient criteria establish International Myeloma Working Group ( IMWG ) ( Rajkumar V et al . Lancet International Myeloma Working Group update criterion diagnosis multiple myeloma . Lancet 2014 ; 15 : 538548 ) 3 . Written confirmation BRAFV600E mutation BRAFV600K mutation majority myeloma cell , define positive IHC staining mutation specific antibody ≥ 50 % respective biopsy , confirm DNA sequence correspond codon 4 . Measurable disease , define : Measurable level myeloma paraprotein serum ( ≥ 0.5 g/dL ) urine ( ≥ 0.2 g/24 hour ) FLC involve light chain &gt; 100mg/l abnormal FLCratio 5 . Age ≥18 6. WHO performance status 03 ( WHO 3 allow cause MM comorbid condition ) ( see Appendix 3 ) 7 . Negative pregnancy test within 72 hour inclusion ( woman childbearing potential ) : For men woman childbearing potential : patient must willing capable use adequate contraception complete therapy ( see also exclusion criterion ) . 8 . All patient must agree abstain donate blood study 9 . Adequate cardiac function : leave ventricular ejection fraction ( LVEF ) ≥ 50 % determined echocardiogram , QTc interval ≤ 450 m 10 . Ability subject take oral medication 11 . Ability subject understand character individual consequence clinical trial 1 . Patient prior treatment MEK and/or RAF inhibitor 2 . Systemic AL amyloidosis ( except patient AL amyloidosis skin bone marrow ) 3 . Patients meningeosis central nervous system lesion ( ) cause multiple myeloma . However , patient treat stereotactic radiotherapy surgery eligible patient remain without evidence CNS disease progression ≥ 4 week . 4 . History current evidence retinal vein occlusion ( RVO ) predispose factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) 5 . History retinal degenerative disease 6 . Plasma cell leukaemia require presence 20 % plasma cell peripheral blood leukocyte least 2/nl . 7 . Patient receive radiotherapy ( include therapeutic radioisotope ) ≤ 21 day , restrict single osteolytic lesion , recover side effect therapy . 8 . Patient major surgery within 21 day prior start study drug recover major side effect surgery . Kyphoplasty prevention skeletal related event allow . 9 . Patient concurrently use approve antineoplastic investigational agent last 14 day prior start treatment . Note : patient may receive cumulative dose 160 mg dexamethasone equivalent emergency therapy within 4 week prior study entry . 10 . Impaired cardiovascular function clinical significant cardiovascular disease include follow : Symptomatic chronic heart failure , history current evidence clinically significant cardiac arrhythmia and/or conduction abnormality &lt; 6 month prior Screening except atrial fibrillation paroxysmal supraventricular tachycardia ; 1 . LVEF &lt; 50 % determined ECHO , uncontrolled hypertension despite medical treatment ( please refer WHO ISH guideline ) 2 . Clinically significant rest bradycardia , unstable angina pectoris ≤ 3 month prior start study drug , history acute coronary syndrome ( include myocardial infarction , coronary artery bypass grafting , coronary angioplasty , stenting ) &lt; 6 month prior screen 3 . QTcF &gt; 450 msec 4. patient acute diffuse infiltrative pulmonary pericardial disease 11 . Significant hepatic dysfunction ( serum bilirubin ≥ 2 mg/dl ASAT and/or ALAT ≥ 2.5 time normal level ) , unless relate myeloma 12 . Active hepatitis B , and/or active hepatitis C infection 13 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LGX818/MEK162 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 14 . Gilbert´s syndrome 15 . Patients neuromuscular disorder associate elevated CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) 16 . Patients plan embark new strenuous exercise regimen first dose study treatment . Note : Muscular activity , strenuous exercise , result significant increase plasma CK level avoid MEK162 treatment 17 . Patients know HIVpositive 18 . Patients active , uncontrolled infection ( patient successful treated antimicrobial therapy may enrol discretion investigator ) . 19 . Patient receive chronic treatment systemic steroid another immunosuppressive agent start study treatment . Note : Topical application ( e.g. , rash ) , inhale spray ( e.g. , obstructive airway disease ) , eye drop local injection ( e.g. , intraarticular ) use systemic steroid prednisone equivalent 10 mg daily allow . 20 . Patient consume Seville orange , grapefruit , grapefruit hybrid , pomelo exotic citrus fruit ( well juice ) last 7 day prior start treatment . Regular orange juice permit . 21 . Second malignancy within past 3 year except : 1 . Adequately treat basal cell squamous cell skin cancer ( adequate wound healing require prior entry study ) 2 . Adequately treated carcinoma situ cervix , 3 . Prostate Cancer require systemic treatment antihormonal treatment PSAlevel upper level normal range . 4 . Ductal breast carcinoma situ full surgical resection ( i.e. , negative margin ) , 5. solid tumor treat curatively , without evidence recurrence least 3 year prior study entry 6 . Similar condition expectation &gt; 95 % 5year disease free survival 22 . Patients follow laboratory value Screening/Baseline . 1 . Absolute neutrophil count ( ANC ) &lt; 1,000/mm3 [ 1.0 x 109/L ] without Growth factor support last 7 day 2 . Platelets ≤ 50000/mm3 [ 50 x 109/L ] ; patient platelets 75000 50000/ mm3 eligible thrombocytopenia confirm related myeloma bone marrow infiltration pt . able receive thrombocyte concentrate 3 . Hemoglobin &lt; 8.0 g/ dl ( unless confirm related myeloma bone marrow infiltration pt . able receive blood transfusion ) 4 . Serum creatinine &gt; 2 x ULN calculate directly measure CrCl ≤ 45 ml/min ; patient creatininclearance 3045 ml/min enrol approval coordinate investigator . 23 . Clinically significant autoimmune haemolytic anaemia positive Coombs test immune thrombocytopenia 24 . Patient woman childbearing potential , UNLESS use double barrier method birth control throughout trial . 1 . Hormonal contraceptive may affect cytochrome P450 interaction , therefore consider neither indicated effective . 2 . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper ) , sponge spermicide . 3 . Reliable contraception maintain throughout study 12 week study drug discontinuation . 4 . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL surgical bilateral oophorectomy ( without hysterectomy ) least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential 25 . Sexually active male unless agree use condom intercourse take drug . This practice continue another 12 week stop treatment . Also father child study period 12 week post study time . A condom also require used vasectomize men order prevent delivery drug via seminal fluid ; 26 . Medical , psychiatric , cognitive condition may compromise patient 's ability understand patient information , give informed consent , comply study protocol complete study . 27 . Patients take nontopical medication know strong inhibitor CYP3A4 . However patient either discontinue treatment switch another medication least three day prior registration eligible . 28 . Participation clinical trial within 1 month prior enrolment except patient supportive care study vaccination study . This include longterm followup period without active drug treatment previous study last 6 month . 29 . Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment contraindicate participation clinical study ( e.g . uncontrolled diabetes , chronic pancreatitis , active chronic hepatitis ) . No subject allow enrolled trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>